FibroBiologics (FBLG) Stock Price, News & Analysis

Company Overview

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Key Stats

• Today's Range: $1.06 to $1.20
• 50-Day Range: $0.99 to $8.70
• 52-Week Range: $0.95 to $22.60
• Volume: 209,255 shs
• Average Volume: 409,783 shs
• Market Capitalization: $5.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $74.00
• Consensus Rating: Hold

FibroBiologics Stock Analysis - MarketRank™

FibroBiologics scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

FibroBiologics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.

Upside Potential

FibroBiologics has a consensus price target of $74.00, representing about 6,751.9% upside from its current price of $1.08.

Amount of Analyst Coverage

FibroBiologics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for FibroBiologics are expected to decrease in the coming year, from ($4.41) to ($4.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of FibroBiologics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of FibroBiologics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

FibroBiologics has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.51% of the float of FibroBiologics has been sold short.

Short Interest Ratio / Days to Cover

FibroBiologics has a short interest ratio ("days to cover") of 0.64, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in FibroBiologics has recently increased by 18.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

FibroBiologics does not currently pay a dividend.

Dividend Growth

FibroBiologics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.47

News Sentiment

FibroBiologics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for FibroBiologics this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for FBLG on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

1 people have added FibroBiologics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

4 insiders have purchased shares of FibroBiologics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $72,886.00 in company stock, which represents 1.2953% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, FibroBiologics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $72,886.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

9.30% of the stock of FibroBiologics is held by insiders.

Percentage Held by Institutions

FibroBiologics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/30/2026
• Today: 5/15/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FBLG
• Previous Symbol: NASDAQ:FBLG
• CIK: 1958777
• Web: www.fibrobiologics.com
• Phone: 281-671-5150
• Fax: N/A
• Employees: 10
• Year Founded: 2021

Price Target and Rating

• Average Price Target for FibroBiologics: $74.00
• High Price Target: $140.00
• Low Price Target: $8.00
• Potential Upside/Downside: +6,751.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -767.07%
• Return on Assets: -195.56%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.59
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.50 per share
• Price / Book: 2.16

Miscellaneous

• Outstanding Shares: 5,210,000
• Free Float: 4,725,000
• Market Cap: $5.63 million
• Optionable: N/A
• Beta: 1.16